Atara Biotherapeutics, Inc. (ATRA)
Largest Insider Buys in Sector
ATRA Stock Price History Chart
ATRA Stock Performance
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies …
Insider Activity of Atara Biotherapeutics, Inc.
Over the last 12 months, insiders at Atara Biotherapeutics, Inc. have bought $0 and sold $224,137 worth of Atara Biotherapeutics, Inc. stock.
On average, over the past 5 years, insiders at Atara Biotherapeutics, Inc. have bought $347,627 and sold $1.04M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 90,980 shares for transaction amount of $28,186 was made by Gallagher Carol Giltner (director) on 2023‑11‑14.
List of Insider Buy and Sell Transactions, Atara Biotherapeutics, Inc.
| 2024-08-16 | Sale | President and CEO | 3,038 0.053% | $6.63 | $20,139 | -0.07% | ||
| 2024-08-16 | Sale | EVP, Chief Sci. & Tech Officer | 1,821 0.0318% | $6.63 | $12,072 | -0.07% | ||
| 2024-08-16 | Sale | EVP, Chief Legal Officer | 1,158 0.0202% | $6.63 | $7,677 | -0.07% | ||
| 2024-08-16 | Sale | EVP, CFO | 1,070 0.0187% | $6.63 | $7,093 | -0.07% | ||
| 2024-08-16 | Sale | EVP, Global Head RA & Quality | 963 0.0168% | $6.63 | $6,384 | -0.07% | ||
| 2024-05-16 | Sale | President and CEO | 81,506 0.0671% | $0.62 | $50,289 | -39.46% | ||
| 2024-05-16 | Sale | EVP, Chief Sci. & Tech Officer | 42,899 0.0353% | $0.62 | $26,469 | -39.46% | ||
| 2024-05-16 | Sale | EVP, Chief Legal Officer | 32,401 0.0267% | $0.62 | $19,991 | -39.46% | ||
| 2024-05-16 | Sale | EVP, CFO | 28,648 0.0236% | $0.62 | $17,676 | -39.46% | ||
| 2024-05-16 | Sale | EVP, Global Head RA & Quality | 25,750 0.0212% | $0.62 | $15,888 | -39.46% | ||
| 2024-03-04 | Sale | President and CEO | 24,844 0.0185% | $0.72 | $17,888 | -35.22% | ||
| 2024-03-04 | Sale | EVP, Chief Sci. & Tech Officer | 10,746 0.008% | $0.72 | $7,737 | -35.22% | ||
| 2024-03-04 | Sale | EVP, Chief Legal Officer | 10,044 0.0075% | $0.72 | $7,232 | -35.22% | ||
| 2024-03-04 | Sale | EVP, CFO | 6,679 0.005% | $0.72 | $4,810 | -35.22% | ||
| 2024-03-04 | Sale | EVP, Global Head RA & Quality | 3,879 0.0029% | $0.72 | $2,793 | -35.22% | ||
| 2023-11-16 | Sale | President and CEO | 20,409 0.0161% | $0.39 | $7,939 | +19.73% | ||
| 2023-11-16 | Sale | EVP, Chief Sci. & Tech Officer | 8,856 0.007% | $0.39 | $3,445 | +19.73% | ||
| 2023-11-16 | Sale | EVP, Chief Legal Officer | 8,307 0.0065% | $0.39 | $3,231 | +19.73% | ||
| 2023-11-16 | Sale | SVP, CFO | 11,958 0.0094% | $0.39 | $4,652 | +19.73% | ||
| 2023-11-16 | Sale | EVP, Chief Medical Officer | 12,287 0.0097% | $0.39 | $4,780 | +19.73% |
Insider Historical Profitability
| Domain Partners VIII, L.P. | 10 percent owner | 2141542 37.1812% | $10.56 | 1 | 0 | +169.68% |
| MARCUS JOEL S | director | 888355 15.4235% | $10.56 | 3 | 3 | +73.99% |
| DOBMEIER ERIC | director | 563325 9.7804% | $10.56 | 4 | 0 | <0.0001% |
| Gallagher Carol Giltner | director | 459418 7.9764% | $10.56 | 4 | 18 | +129.11% |
| HEIDEN WILLIAM K | director | 209000 3.6286% | $10.56 | 1 | 0 |
Institutional Investor Ownership
| Ecor1 Capital Llc | $7.06B | 207.31 | 10.17M | +0.99% | +$69.4M | 49.51 | |
| Redmile Group | $6.43B | 188.88 | 9.26M | +1.72% | +$108.86M | 65.63 | |
| BlackRock | $4.74B | 139.3 | 6.83M | -3.61% | -$177.48M | 0.1 | |
| Bank of America | $4.57B | 134.18 | 6.58M | +3,379.43% | +$4.44B | 0.44 | |
| Citadel Advisors LLC | $4.52B | 132.78 | 6.51M | +2,375.59% | +$4.34B | 2.58 |